Public market insider buying at Avicanna (T:AVCN)

Sheldon Inwentash, a 10% Holder, acquired 1,049,500 Common Shares on a control or direction basis for registered holder ThreeD Capital at prices ranging from $0.364 to $0.399 between September 30th, 2024 and October 2nd, 2024. This represents a $412,907 investment into the company's shares and an account share holdings change of 12.1%.

Brownstone Energy Inc., a 10% Holder, acquired 231,000 Common Shares on a direct ownership basis at a price of $0.398 on October 2nd, 2024. This represents a $91,961 investment into the company's shares and an account share holdings change of 2.4%.

Avicanna is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients' needs and enhances the patient's journey. Avicanna Inc. (AVCN) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, two insiders have invested a total amount of $504,868.